⁤A collaborative team of neuroscientists, biochemists, and Alzheimer’s specialists from the United States and Icelandic institutions has developed a protein map to identify early markers for Alzheimer’s disease in cerebrospinal fluid. ⁤⁤Published in Science Translational Medicine, their study used high-resolution scanning technology to uncover potential precursors to the disease, potentially allowing for early diagnosis long before symptoms appear. ⁤

⁤Alzheimer has been linked to amyloid-beta and tau protein accumulations in the brain. ⁤⁤Traditional methods only detect these proteins once the disease has progressed significantly. ⁤⁤The new approach analyzed thousands of cerebrospinal fluid samples from 160 individuals at various Alzheimer’s stages using advanced mass spectrometry and SomaScan assays. ⁤⁤The researchers created 34 testing modules, revealing a correlation between Alzheimer’s and the genetic risk factor APOE ɛ4. ⁤⁤This breakthrough suggests the possibility of identifying Alzheimer’s up to 20 years before current methods, providing a larger window for early intervention. ⁤

To read more, click here. 

[Source: Science Translational Medicine, June 26th 2024.]